That seems entirely appropriate mark.
If the O.S. result in Q4 shows this level of benefit improvement, I'll be dusting off an old Grange.
I'm trying to recall what the PFS benefit for Provenge was prior to FDA approval and if memory serves it was around 3 months over OSC. Cvac seems to have shown that a clean pair of heels.
expected announcment 14th, page-39
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $501.1M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 34.8¢ | 33.5¢ | $198.3K | 578.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 70769 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 335387 | 16 |
View Market Depth
| Last trade - 14.08pm 29/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |